Sayeef Mirza, MD, MPH

Cancer Focus:
Autoimmune Disorders, Hodgkin Lymphoma, Leukemia, Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma

Dr. Mirza received his MD degree from the University of South Florida, Morsani College of Medicine. He completed an Internal Medicine Residency at University of South Florida, where he also served as Chief Resident. Dr. Mirza most recently completed a Hematology/Oncology Clinical Fellowship at Yale University, Smilow Cancer Hospital, New Haven, Connecticut.

 

Dr. Mirza’s clinical interests involve optimizing cellular therapies for hematologic malignancies. He is also interested in optimizing immune reconstitution and regulating the immune system to maximize long-term clinical outcomes. Dr. Mirza’s research has been focused on toxicities associated with hematopoietic stem cell transplantation and cellular therapies for different types of leukemia and lymphoma. He has been actively involved in both single institutional experiences and multi-institutional registry studies as well as translational studies.

Education & Training

Fellowship:

• Yale University - Hematology & Medical Oncology

Residency:

• University of South Florida - Internal Medicine

Medical School:

• University of South Florida

Clinical Trial 23456
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (CTN 2203)
Condition: Immunotherapy
Intervention: Alkeran (Melphalan); Cellcept (Mycophenolate Mofetil); FK506 (Tacrolimus); Jakafi (Ruxolitinib); Melphalan (); Mycophenolate Mofetil (); Radiotherapy (); Ruxolitinib (); Tacrolimus (); busulfan (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); methotrexate ()
Status: OPEN (SUSPENDED)

Clinical Trial 23614
A Phase 2, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted NEXTCAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)
Condition: Immunotherapy
Intervention: CC-97540 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Schmitz J, Gaskill E, Price S, Cao B, Kim J, Baluch A, Klinkova O, Faramand R, Mishra A, Perez L, Khimani F, Lazaryan A, Ochoa-Bayona JL, Liu H, Mirza AS, Nieder M, Anasetti C, Nishihori T, Pidala JA, Bejanyan N, Elmariah H. Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide. Bone Marrow Transplant. 2025 Oct.60(10):1383-1386. Pubmedid: 40617898.
• Hunter BD, Lunning M, Shadman M, Ahmed S, Abramson JS, Perales MA, Ahmed N, Mirza AS, Isufi I, Frigault MJ, Crombie JL, Miklos DB, Vasconcelos A, Crotta A, Bernasconi D, Roy D, Bleickardt E, Pasquini MC, Kamdar M. CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting. Transplant Cell Ther. 2025 Oct. Pubmedid: 41235976.
• Sidana S, Ahmed N, Akhtar OS, Brazauskas R, Oloyede T, Bye M, Hansen DK, Ferreri CJ, Freeman CL, Afrough A, Anderson LD, Dhakal B, Dhanda DS, Gowda L, Hashmi H, Harrison MJ, Kitali A, Landau HJ, Mirza AS, Patwardhan P, Qazilbash MH, Usmani SZ, Patel KK, Nishihori T, Ganguly S, Pasquini MC. Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma. Blood. 2025 Jul.146(2):167-177. Pubmedid: 40198886.
• Shouval R, Strouse C, Kim S, Oloyede T, Ahmed S, Awan FT, Luan D, Bachanova V, Badar T, Bar M, Barba P, Beitinjaneh AM, Cashen A, Dholaria B, Elsawy M, Ganguly S, Geethakumari PR, Greenbaum U, Hashmi H, Hill LC, Jain MD, Jain T, Kebriaei P, Kittai AS, Locke FL, Lulla PD, Mead E, McGuirk JP, Mussetti A, Nishihori T, Olson AL, Pennisi M, Perales MA, Riedell PA, Saber W, Mirza AS, Magalhaes-Silverman M, Shpall EJ, Sorror M, Wudhikarn K, Turtle CJ, Moskop A, Pasquini MC. Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma. Transplant Cell Ther. 2025 Jul.31(7):419-433. Pubmedid: 40288610.
• Akhtar OS, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, Ahmed N, Bye M, Hansen DK, Ferreri CJ, Dhakal B, Dhanda DS, Harrison MJ, Kitali A, Landau HJ, Mirza AS, Patel J, Patwardhan P, Qazilbash MH, Patel KK, Nishihori T, Ganguly S, Gowda L, Anderson LD, Pasquini MC, Usmani SZ, Freeman CL. Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study. Blood Adv. 2025 Apr.9(7):1587-1592. Pubmedid: 39786391. Pmcid: PMC11986210.
• Handley G, Yepes A, Eliassen E, Dominguez G, Pasikhova Y, Klinkova O, Baluch A, Febres-Aldana AJ, Alsina M, Elmariah H, Khimani F, Hansen DK, Freeman CL, Jain MD, Locke F, Lazaryan A, Liu HD, Mishra A, Mirza AS, Nishihori T, Ochoa L, Perez L, Pidala J, Puglianini OC, Nieder M, Perna F, Kim J, Bejanyan N, Faramand R. Outcomes of Haploidentical Stem Cell Transplant Recipients With HHV-6B Reactivation. Open Forum Infect Dis. 2024 Oct.11(10):ofae564. Pubmedid: 39411216. Pmcid: PMC11475747.
• Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB, Perales MA, Munoz J, Fingrut WB, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza AS, Abid MB, Hong S, Majhail NS, Kharfan-Dabaja MA, Khurana A, Badar T, Lin Y, Bennani NN, Herr MM, Hu ZH, Wang H, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini MC. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity. Blood. 2024 Jun.143(26):2722-2734. Pubmedid: 38635762. Pmcid: PMC11251200.
• Mirza AS, Lazaryan A. Minimalist approach to conditioning intensity for allogeneic transplantation of patients with non-Hodgkin Lymphoma: if less is more, than how low do we go?. Transplant Cell Ther. 2024 Jan.30(1):11-13. Pubmedid: 38185504.
• Leveille E, Chan LN, Mirza AS, Kume K, Müschen M. SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies. Cell Signal. 2022 Jun.94:110331. Pubmedid: 35398488.
• MacDonald M, Mirza AS, Mhaskar R, Ewing A, Chen L, Robinson K, Lu Y, Ayoubi N, Gonzalez E, Guerra L, Roetzheim R, Woodard L, Pabbathi S. Preventative Cancer Screening Rates Among Uninsured Patients in Free Clinics: A Retrospective Cohort Study of Cancer Survivors and Non-cancer Survivors. Cancer Control. 2022 Jan.29. Pubmedid: 35245986. Pmcid: PMC8902193.
• Mirza AS, Tandon A, Jenneman D, Cao S, Brimer T, Kumar A, Kidd M, Khimani F, Faramand R, Mishra A, Liu H, Nishihori T, Perez L, Lazaryan A, Bejanyan N, Nieder M, Pidala J, Elmariah H. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022 Apr.28(4):185.e1-185.e7. Pubmedid: 35017119.
• Nguyen M, Dyjak P, MacDonald M, Vivar J, Shah S, Swanson J, Pruitt Z, Mirza AS, Mhaskar R. Treatment of Pharyngitis in Uninsured Patients: A Multicenter Study of Free Clinics. Cureus. 2021 Oct.13(10):e18564. Pubmedid: 34760411. Pmcid: PMC8571809.
• Mushtaq S, Prabakaran S, Elharake M, Mirza S, Ravindran A, Faramand R, Sokol L. Primary Effusion Lymphoma: Small Bowel Recurrence After Stem Cell Transplant. ACG Case Rep J. 2021 Nov.8(11):e00698. Pubmedid: 34820467. Pmcid: PMC8608261.
• Mirza AS, Kumar A, Hashmi H, Garcia F, Logothetis CN, Darwin A, Faramand R, Reid K, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Nishihori T, Locke FL, Jain MD. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. Transplant Cell Ther. 2021 Mar.27(3):242.e1-242.e6. Pubmedid: 33781520.
• Rahman S, Mirza AS, Wathington D, Green S, Mayers Y, Iranmanesh E, Woodard L. Chronic disease and socioeconomic factors among uninsured patients: A retrospective study. Chronic Illn. 2021 Mar.17(1):53-66. Pubmedid: 30782011.
• Mathews AT, Mirza AS, Bohra C, Mathews AG, Ritucci-Chinni P, L Weber J, W Bulkeley W, Siddique M, Whitaker D, Bowerman R. Diagnosing Cardiac Amyloidosis: From Heart Failure to Electrical Storm. Case Rep Med. 2021 Jun.2021:3293728. Pubmedid: 34239572. Pmcid: PMC8238623.
• Rivera Rivero B, Makarova A, Sidig D, Niazi S, Abddelgader R, Mirza S, Joud H, Urfi M, Ahmed A, Jureyda O, Khan F, Swanson J, Siddique M, Weare-Regales N, Mirza AS. Nutritional Literacy Among Uninsured Patients With Diabetes Mellitus: A Free Clinic Study. Cureus. 2021 Jul.13(7):e16355. Pubmedid: 34414041. Pmcid: PMC8364779.
• Joud H, Mohamed E, Mirza S, Tabbaa H, Tabbaa M, Khan F, Ayoubi N, MacDonald M, Woodard L, Oxner A, Guerra L, Bakour C, Mirza AS. Prevalence and management of diabetes among the uninsured: A multicenter study in Tampa Bay, FL. Diabetes Res Clin Pract. 2021 Jan.171:108560. Pubmedid: 33271229.
• Song EY, Swanson J, Patel A, MacDonald M, Aponte A, Ayoubi N, Guerra L, Gonzalez E, Mhaskar R, Mirza AS. Colorectal Cancer Risk Factors and Screening Among the Uninsured of Tampa Bay: A Free Clinic Study. Prev Chronic Dis. 2021 Feb.18:E16. Pubmedid: 33630731. Pmcid: PMC7938966.
• Bewersdorf JP, Allen C, Mirza AS, Grimshaw AA, Giri S, Podoltsev NA, Gowda L, Cho C, Tallman MS, Zeidan AM, Stahl M. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis. Transplant Cell Ther. 2021 Dec.27(12):997.e1-997.e11. Pubmedid: 34551341. Pmcid: PMC9533376.
• Hashmi H, Mirza AS, Darwin A, Logothetis C, Garcia F, Kommalapati A, Mhaskar RS, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Locke FL, Nishihori T, Jain MD. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Adv. 2020 Sep.4(17):4086-4090. Pubmedid: 32877523. Pmcid: PMC7479945.
• MacDonald MR, Zarriello S, Swanson J, Ayoubi N, Mhaskar R, Mirza AS. Secondary prevention among uninsured stroke patients: A free clinic study. SAGE Open Med. 2020 Oct.8. Pubmedid: 33110604. Pmcid: PMC7564623.
• Liu N, Mathews A, Swanson J, Mhaskar R, Mathews A, Ayoubi N, Mirza AS. Aspirin use for cardiovascular disease prevention in the uninsured population. SAGE Open Med. 2020 Jun.8. Pubmedid: 32647578. Pmcid: PMC7328214.
• MacDonald M, Shah S, Swanson J, Song E, Ahsan T, Pabbathi S, Mhaskar R, Mirza AS. Substance Use in Uninsured Cancer Survivors: A Multicenter Cross-Sectional Study of Free Clinics. Cureus. 2020 Aug.12(8):e10083. Pubmedid: 33005507. Pmcid: PMC7522175.
• Mirza AS, Horna P, Teer JK, Song J, Akabari R, Hussaini M, Sokol L. New Insights Into the Complex Mutational Landscape of Sézary Syndrome. Front Oncol. 2020 Apr.10:514. Pubmedid: 32373524. Pmcid: PMC7186303.
• Mirza AS, Chen L, Amirzadeh S, Majethia S, Joppen J, Mirza S, Mhaskar R, Jaglal M, Ashraf N. Health disparities and chronic disease associated with anemia in free clinics: A retrospective study of uninsured patients in Tampa Bay. Postgrad Med. 2019 Sep.131(8):612-618. Pubmedid: 31524033.
• Mirza AS, Dholaria BR, Hussaini M, Mushtaq S, Horna P, Ravindran A, Kumar A, Ayala E, Kharfan-Dabaja MA, Bello C, Chavez JC, Sokol L. High-dose Therapy and Autologous Hematopoietic Cell Transplantation as Consolidation Treatment for Primary Effusion Lymphoma. Clin Lymphoma Myeloma Leuk. 2019 Sep.19(9):e513-e520. Pubmedid: 31253594.
• Mirza AS, Yun S, Ali NA, Shin H, O'Neil JL, Elharake M, Schwartz D, Robinson K, Nowell E, Engle G, Badat I, Brimer T, Kuc A, Sequeira A, Mirza S, Sikaria D, Vera JD, Hackney N, Abusrur S, Jesurajan J, Kuang J, Patel S, Khalil S, Bhaskar S, Beard A, Abuelenen T, Ratnasamy K, Visweshwar N, Komrokji R, Jaglal M. Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experience. Thromb J. 2019 Jul.17:13. Pubmedid: 31303864. Pmcid: PMC6604148.
• Ayoubi N, Mirza AS, Swanson J, Hamoui R, Mhaskar R. Dermatologic care of uninsured patients managed at free clinics. J Am Acad Dermatol. 2019 Aug.81(2):433-437. Pubmedid: 30878564.
• Pribish A, Khalil N, Mhaskar R, Woodard L, Mirza AS. Chronic Disease Burden of the Homeless: A Descriptive Study of Student-Run Free Clinics in Tampa, Florida. J Community Health. 2019 Apr.44(2):249-255. Pubmedid: 30324539.
• Mirza AS, Pabbathi S, Lu Y, Ayoubi N, Ewing A, Jaglal M, Roetzheim R. Comorbidities, risk, and socioeconomic factors of uninsured cancer survivors. Medicine. 2018 Nov.97(47):e13121. Pubmedid: 30461610. Pmcid: PMC6393034.
• Hussaini MO, Mirza AS, Komrokji R, Lancet J, Padron E, Song J. Genetic Landscape of Acute Myeloid Leukemia Interrogated by Next-generation Sequencing: A Large Cancer Center Experience. Cancer Genomics Proteomics. 2018 Mar.15(2):121-126. Pubmedid: 29496691. Pmcid: PMC5892606.
• Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver N. Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma. 2018 Jul.59(7):1672-1676. Pubmedid: 29119847.
• Markow M, Mirza AS, Perez L, Shao H, Horna P, Anasetti C, Sokol L, Hussaini MO. Transformation of T-Cell Acute Lymphoblastic Lymphoma to Peripheral T-Cell Lymphoma: A Report of Two Cases. Case Rep Hematol. 2018 Feb.2018:9191582. Pubmedid: 29682368. Pmcid: PMC5850893.
• Rahman S, Mirza AS, Stenback J, Green S, Mayers Y, Iranmanesh E, Pribish A, Islam S, Woodard L. Burden of Chronic Conditions among Patients from Free Clinics: A Retrospective Chart Review of 2015. J Health Care Poor Underserved. 2018 Dec.29(3):1011-1026. Pubmedid: 30122680.
• Mirza AS, Rodriguez VV. Cave diving for a diagnosis: Disseminated histoplasmosis in the immunocompromised. IDCases. 2018 Apr.12:92-94. Pubmedid: 29942759. Pmcid: PMC6010963.
• Mirza AS, Verma S, Fu L, Bassil C. Thrombotic Microangiopathy With Granulomatosis Interstitial Nephritis in an Allogenic Bone Marrow Transplant Patient: A Case Report and Review of the Literature. J Hematol (Brossard). 2017 Sep.6(2-3):52-58. Pubmedid: 32300393. Pmcid: PMC7155822.
• Mirza S, Hill E, Ludlow SP, Nanjappa S. Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome. Melanoma Res. 2017 Jun.27(3):271-273. Pubmedid: 28146044.
• Mirza AS, Lancet JE, Sweet K, Padron E, Pinilla-Ibarz J, Nardelli L, Cubitt C, List AF, Komrokji RS. A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec.17(12):902-907. Pubmedid: 29030092.
• Hussaini M, Yeung C, Zhu X, Mirza AS, Pfeifer J, Hassan A. PRDM1 expression levels in marginal zone lymphoma and lymphoplasmacytic lymphoma. Int J Clin Exp Pathol. 2017 Aug.10(8):8610-8618. Pubmedid: 31966717. Pmcid: PMC6965379.
• Fang B, Hoffman MA, Mirza AS, Mishall KM, Li J, Peterman SM, Smalley KS, Shain KH, Weinberger PM, Wu J, Rix U, Haura EB, Koomen JM. Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides. Methods. 2015 Jun.81:41-49. Pubmedid: 25782629. Pmcid: PMC4460980.

• Title: A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity
  Award Number: N/A
  Sponsor: Medical College of Virginia Foundation (MCVF)
  Mirza, A. (PD/PI), Pidala, J. ()